Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
M.D. Anderson Cancer Center
With
National Cancer Institute (NCI)
PRIMARY OBJECTIVES:
I. Identify the rate of SLN (sentinel lymph node) positivity for eyelid sebaceous gland carcinomas.
II. Identify the false negative events associated with SLN biopsy for sebaceous gland carcinomas.
SECONDARY OBJECTIVE:
I. Record any side effects associated with SLN biopsy for sebaceous gland carcinoma of the eyelid.
OUTLINE:
Patients receive technetium Tc 99m sulfur colloid intradermally (ID) and then undergo lymph node mapping and SLN biopsy.
After completion of study treatment, patients are followed up every 3 months for 1 year and then every 6 months for 4 years.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Possible or suspicious sebaceous gland carcinoma of the eyelid
A CXR (chest x-ray), liver enzymes, and a head and neck computed tomography (CT), a single photon emission computed tomography (SPECT/CT) or magnetic resonance imaging (MRI) and an ultrasound negative for clinical evidence of metastasis
Patient provided written informed consent; in the event that non-English speaking participants are eligible for this study, a short form (if applicable) or an informed consent document (ICD) in their language, will be utilized and completed in accordance with the M.D. Anderson Cancer Center (MDACC) Policy for Consenting Non-English Speaking Participants
